168 related articles for article (PubMed ID: 16585220)
21. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
22. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase.
Park MJ; Park IC; Hur JH; Kim MS; Lee HC; Woo SH; Lee KH; Rhee CH; Hong SI; Lee SH
J Neurosurg; 2002 Jul; 97(1):112-8. PubMed ID: 12134900
[TBL] [Abstract][Full Text] [Related]
23. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
24. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
25. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A.
Dabizzi S; Noci I; Borri P; Borrani E; Giachi M; Balzi M; Taddei GL; Marchionni M; Scarselli GF; Arcangeli A
Cancer Res; 2003 Jul; 63(14):4281-6. PubMed ID: 12874038
[TBL] [Abstract][Full Text] [Related]
27. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
Kikkawa F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells.
Sato T; Koike L; Miyata Y; Hirata M; Mimaki Y; Sashida Y; Yano M; Ito A
Cancer Res; 2002 Feb; 62(4):1025-9. PubMed ID: 11861377
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway.
Choi JH; Chen CL; Poon SL; Wang HS; Leung PC
Endocr Relat Cancer; 2009 Mar; 16(1):179-88. PubMed ID: 19022848
[TBL] [Abstract][Full Text] [Related]
30. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
Gwak HS; Park MJ; Park IC; Woo SH; Jin HO; Rhee CH; Jung HW
J Neurosurg; 2014 Dec; 121(6):1483-91. PubMed ID: 25303017
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
[TBL] [Abstract][Full Text] [Related]
32. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
So J; Wang FQ; Navari J; Schreher J; Fishman DA
Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
[TBL] [Abstract][Full Text] [Related]
33. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
[TBL] [Abstract][Full Text] [Related]
34. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin.
Schiffenbauer YS; Meir G; Maoz M; Even-Ram SC; Bar-Shavit R; Neeman M
Gynecol Oncol; 2002 Feb; 84(2):296-302. PubMed ID: 11812090
[TBL] [Abstract][Full Text] [Related]
35. Progranulin expression induced by follicle-stimulating hormone in ovarian cancer cell lines depends on the histological subtype.
Perez-Juarez CE; Arechavaleta-Velasco F; Mendez C; Díaz-Cueto L
Med Oncol; 2020 May; 37(7):59. PubMed ID: 32474861
[TBL] [Abstract][Full Text] [Related]
36. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
37. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
38. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.
Rodriguez GC; Haisley C; Hurteau J; Moser TL; Whitaker R; Bast RC; Stack MS
Gynecol Oncol; 2001 Feb; 80(2):245-53. PubMed ID: 11161867
[TBL] [Abstract][Full Text] [Related]
39. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
Zhang A; Meng L; Wang Q; Xi L; Chen G; Wang S; Zhou J; Lu Y; Ma D
Oncol Rep; 2006 Apr; 15(4):831-6. PubMed ID: 16525667
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
